Can We Use <i>Ginkgo biloba</i> Extract to Treat Alzheimer’s Disease? Lessons from Preclinical and Clinical Studies

(1) Background: <i>Ginkgo biloba</i> extract (GBE) has been widely used to treat central nervous system and cardiovascular diseases. Accumulating evidence has revealed the therapeutic potential of GBE against Alzheimer's disease (AD); however, no systematic evaluation has been perfo...

Full description

Bibliographic Details
Main Authors: Liming Xie, Qi Zhu, Jiahong Lu
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cells
Subjects:
Online Access:https://www.mdpi.com/2073-4409/11/3/479
_version_ 1797488503188094976
author Liming Xie
Qi Zhu
Jiahong Lu
author_facet Liming Xie
Qi Zhu
Jiahong Lu
author_sort Liming Xie
collection DOAJ
description (1) Background: <i>Ginkgo biloba</i> extract (GBE) has been widely used to treat central nervous system and cardiovascular diseases. Accumulating evidence has revealed the therapeutic potential of GBE against Alzheimer's disease (AD); however, no systematic evaluation has been performed; (2) Methods: a total of 17 preclinical studies and 20 clinical trials assessing the therapeutic effects of GBE against AD were identified from electronic databases. The data in the reports were extracted to conduct a meta-analysis of the AD-related pathological features or symptoms; (3) Results: For the preclinical reports, 45 animals treated with GBE, in six studies, were subjected to cognitive function assessments by the Morris water maze. GBE was shown to reduce the escape latencies in several studies, in both rats and mice (I<sup>2</sup> > 70%, <i>p</i> < 0.005). For the clinical trials, eight trials, including 2100 individuals, were conducted. The results show that GBE improved the SKT and ADAS-Cog scores in early-stage AD patients after high doses and long-term administration; (4) Conclusions: GBE displayed generally consistent anti-AD effects in animal experiments, and it might improve AD symptoms in early-stage AD patients after high doses and long-term administration. A lack of sample size calculations and the poor quality of the methods are two obvious limitations of the studies. Nevertheless, the preclinical and clinical data suggest that further large-scale clinical trials may be needed in order to examine the effects of long-term GEB administration on early-stage AD.
first_indexed 2024-03-10T00:03:06Z
format Article
id doaj.art-3f97947f6504406b83eaea9218750f0c
institution Directory Open Access Journal
issn 2073-4409
language English
last_indexed 2024-03-10T00:03:06Z
publishDate 2022-01-01
publisher MDPI AG
record_format Article
series Cells
spelling doaj.art-3f97947f6504406b83eaea9218750f0c2023-11-23T16:12:38ZengMDPI AGCells2073-44092022-01-0111347910.3390/cells11030479Can We Use <i>Ginkgo biloba</i> Extract to Treat Alzheimer’s Disease? Lessons from Preclinical and Clinical StudiesLiming Xie0Qi Zhu1Jiahong Lu2State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau SAR 999078, ChinaState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau SAR 999078, ChinaState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau SAR 999078, China(1) Background: <i>Ginkgo biloba</i> extract (GBE) has been widely used to treat central nervous system and cardiovascular diseases. Accumulating evidence has revealed the therapeutic potential of GBE against Alzheimer's disease (AD); however, no systematic evaluation has been performed; (2) Methods: a total of 17 preclinical studies and 20 clinical trials assessing the therapeutic effects of GBE against AD were identified from electronic databases. The data in the reports were extracted to conduct a meta-analysis of the AD-related pathological features or symptoms; (3) Results: For the preclinical reports, 45 animals treated with GBE, in six studies, were subjected to cognitive function assessments by the Morris water maze. GBE was shown to reduce the escape latencies in several studies, in both rats and mice (I<sup>2</sup> > 70%, <i>p</i> < 0.005). For the clinical trials, eight trials, including 2100 individuals, were conducted. The results show that GBE improved the SKT and ADAS-Cog scores in early-stage AD patients after high doses and long-term administration; (4) Conclusions: GBE displayed generally consistent anti-AD effects in animal experiments, and it might improve AD symptoms in early-stage AD patients after high doses and long-term administration. A lack of sample size calculations and the poor quality of the methods are two obvious limitations of the studies. Nevertheless, the preclinical and clinical data suggest that further large-scale clinical trials may be needed in order to examine the effects of long-term GEB administration on early-stage AD.https://www.mdpi.com/2073-4409/11/3/479<i>Ginkgo biloba</i> extractAlzheimer’s diseaseclinical trialmeta-analysis
spellingShingle Liming Xie
Qi Zhu
Jiahong Lu
Can We Use <i>Ginkgo biloba</i> Extract to Treat Alzheimer’s Disease? Lessons from Preclinical and Clinical Studies
Cells
<i>Ginkgo biloba</i> extract
Alzheimer’s disease
clinical trial
meta-analysis
title Can We Use <i>Ginkgo biloba</i> Extract to Treat Alzheimer’s Disease? Lessons from Preclinical and Clinical Studies
title_full Can We Use <i>Ginkgo biloba</i> Extract to Treat Alzheimer’s Disease? Lessons from Preclinical and Clinical Studies
title_fullStr Can We Use <i>Ginkgo biloba</i> Extract to Treat Alzheimer’s Disease? Lessons from Preclinical and Clinical Studies
title_full_unstemmed Can We Use <i>Ginkgo biloba</i> Extract to Treat Alzheimer’s Disease? Lessons from Preclinical and Clinical Studies
title_short Can We Use <i>Ginkgo biloba</i> Extract to Treat Alzheimer’s Disease? Lessons from Preclinical and Clinical Studies
title_sort can we use i ginkgo biloba i extract to treat alzheimer s disease lessons from preclinical and clinical studies
topic <i>Ginkgo biloba</i> extract
Alzheimer’s disease
clinical trial
meta-analysis
url https://www.mdpi.com/2073-4409/11/3/479
work_keys_str_mv AT limingxie canweuseiginkgobilobaiextracttotreatalzheimersdiseaselessonsfrompreclinicalandclinicalstudies
AT qizhu canweuseiginkgobilobaiextracttotreatalzheimersdiseaselessonsfrompreclinicalandclinicalstudies
AT jiahonglu canweuseiginkgobilobaiextracttotreatalzheimersdiseaselessonsfrompreclinicalandclinicalstudies